Get the Stockscreener App
0.6501
2.26%
-0.0149
Humacyte Inc stock is traded at $0.6501, with a volume of 1.90M.
It is down -2.26% in the last 24 hours and down -5.96% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.665
Open:
$0.641
24h Volume:
1.90M
Relative Volume:
0.19
Market Cap:
$175.29M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.1312
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
-8.40%
1M Performance:
-5.96%
6M Performance:
-35.64%
1Y Performance:
-63.48%
1-Day Range:
$0.641
$0.6775
1-Week Range:
$0.6156
$0.7499
52-Week Range:
$0.5469
$2.55
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.6501 | 179.31M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
525.15 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.09 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.51 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.46 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
358.30 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Canada
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... - Yahoo Finance Australia
Humacyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk - Stock Titan
HUMA Q2 FY2026 earnings call - finance.biggo.com
Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results - MarketBeat
Humacyte stock maintained at Buy by BTIG on pipeline progress - Investing.com Canada
Humacyte Q2 Results: Sales Miss Estimate by 64%, Loss Widens - scanx.trade
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket - Investing.com Canada
HUMA: Breakthrough clinical results and commercial momentum position for growth and new launches in 2027 - TradingView
Humacyte Q2 Earnings Call Highlights - TradingView
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Form 8K Humacyte Inc For: 12 August By Investing.com - Investing.com South Africa
HUMACYTE ($HUMA) Releases Q2 2026 Earnings - Quiver Quantitative
Form 8K Humacyte Inc For: 12 August - Investing.com India
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M - TradingView
Humacyte Reports Breakthrough V012 Dialysis Access Results, FDA Accepts CTEV IND, and Second-Quarter 2026 Financial Results - Quiver Quantitative
Humacyte Q2 revenue rises to $0.4 million as net loss narrows - Quiver Quantitative
BRIEF-Humacyte Q2 Operating Expenses USD 27.402 Million - TradingView
Humacyte (NASDAQ:HUMA): What Could Today’s commercial adoption and manufacturing Update Reveal? - Kalkine Media
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Exp - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Certain Stock Options of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 10-AUG-2026. - marketscreener.com
Humacyte to Announce 2026 Second Quarter Fina - Moomoo
Humacyte to Report Second Quarter 2026 Financial Results and Host Corporate Update Webcast on August 12 - Quiver Quantitative
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 - marketscreener.com
Humacyte, Inc. (HUMA): Investor Outlook on a High-Stakes Biotech with 188.90% Potential Upside - directorstalkinterviews.com
Humacyte Q2 Results: Financial update scheduled for August 12 - scanx.trade
Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Humacyte (HUMA) Expected to Announce Earnings on Monday - MarketBeat
Humacyte, Inc. Revenue Breakdown – NASDAQ:HUMA - TradingView
Humacyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Humacyte, Inc. (HUMA) Stock Analysis: A 205% Potential Upside In Innovative Biotechnology - directorstalkinterviews.com
Humacyte gets Nasdaq notice after shares trade below $1 bid-price minimum - Bitget
BlackRock (NYSE: BLK) discloses 1.5% beneficial stake in Humacyte (HUMA) - Stock Titan
Humacyte, Inc. Revenue Breakdown – NASDAQ:HUMAW - TradingView
Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Humacyte Inc Lobbyists, 2024 - opensecrets.org
Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery - Moomoo
Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FDA accepts Humacyte IND for coronary bypass graft study - Investing.com
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting - The Manila Times
Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass - Stock Titan
Humacyte Inc (HUMA) Cash Flow - TradingKey
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):